Synapse
⌘+K
Synapse
PulseExploreJournal ClubResearchersJournals
Instagram
HomeJournal ClubExplore
June 1, 2024Journal of Clinical Oncology

Clinical significance of circulating tumor DNA in neoadjuvant-treated HER2-negative luminal B breast cancer.

View Full Paper
Ask AI
Bookmark
Share

Authors

YZYunxiang ZhouZZZhiyun ZhangTMTing Ma

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Zhou et al. (2024) studied this question.

synapsesocial.com/papers/68e673f0b6db6435875fe25ehttps://doi.org/10.1200/jco.2024.42.16_suppl.e12616
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Prognostic significance of ctDNA mutation analysis in patients with HER2-positive breast cancer undergoing neoadjuvant chemotherapy.2024
  2. 2Abstract PO4-01-04: Clinical significance of Circulating tumor DNA (ctDNA) analysis in predicting pathologic complete remission in HER2-positive Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy2024
  3. 3Abstract PO2-15-02: Personalized circulating tumor DNA (ctDNA) monitoring can early identify disease progression and predict prognosis in patients with breast cancer undergoing neoadjuvant therapy2024
  4. 4Prognostic Value of Circulating Tumor DNA in HR+/HER2− Stage I–III Breast Cancer: A Systematic Review2025 · 5 citations
  5. 5Abstract 2420: Evaluating circulating tumor DNA (ctDNA) as a prognostic biomarker utilizing a tissue-free epigenomic assay in early-stage triple negative breast cancer (TNBC)2024